Benazepril hydrochloride | CAS#86541-74-4 | ACE Inhibitor

Benazepril hydrochloride
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317310

CAS#: 86541-74-4 (HCl)

Description: Benazepril Hydrochloride is the hydrochloride salt of benazepril, a carboxyl-containing angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Benazeprilat competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II, resulting in vasodilation. Benazeprilat also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow. Benazepril hydrochloride reduces blood pressure and myocardial hypertrophy in spontaneous hypertensive rats.

Chemical Structure

Benazepril hydrochloride

CAS# 86541-74-4 (HCl)

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 317310
Name: Benazepril hydrochloride
CAS#: 86541-74-4 (HCl)
Chemical Formula: C24H29ClN2O5
Exact Mass: 0.00
Molecular Weight: 460.950
Elemental Analysis: C, 62.54; H, 6.34; Cl, 7.69; N, 6.08; O, 17.35

Price and Availability

Size	Price	Availability
100mg	USD 150	2 weeks
200mg	USD 250	2 weeks
500mg	USD 450	2 weeks
1g	USD 650	2 weeks
2g	USD 950	2 weeks
5g	USD 1650	2 weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 86541-75-5 (free base) 86541-74-4 (HCl)

Synonym: Benazepril hydrochloride; Benazepril; benazepril hydrochloride; benzazepril; Briem; CGS-14824-A; CGS-14824A; Cibacène; Cibacen; Labopal; Lotensin

IUPAC/Chemical Name: (3S)-3-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid hydrochloride

InChi Key: VPSRQEHTHIMDQM-FKLPMGAJSA-N

InChi Code: InChI=1S/C24H28N2O5.ClH/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28;/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28);1H/t19-,20-;/m0./s1

SMILES Code: O=C(O)CN1C([C@@H](N[C@H](C(OCC)=O)CCC2=CC=CC=C2)CCC3=CC=CC=C31)=O.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	Benazepril hydrochloride is an angiotensin converting enzyme inhibitor.
In vitro activity:	The effects of combination use of leflunomide and benazepril on diabetic nephropathy (DN) were investigated in vitro. Rat glomerular mesangial cells (RMCs) were treated with high-glucose (150 mg/ml) and the leflunomide and benazepril with both concentrations of 50 μmol/l were used to treat the high-glucose induced cells. Treatment of leflunomide and benazepril significantly reduced expression levels of NF-κB, TGF-β and TRPC6 in high-glucose induced RMCs. It was also observed that leflunomide and benazepril reduced high-glucose induced cell apoptosis of RMCs. Reference: Ren Fail. 2019 Nov;41(1):899-906. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764370/
In vivo activity:	The effects of benazepril hydrochloride (BH) on proteinuria and ANGPTL-4 expression were evaluated in a diabetic nephropathy (DN) rat model. A total of 72 Wistar male rats were randomly divided into three groups: normal control (NC), DN group and BH treatment (BH) groups. Weight was significantly lower but glucose levels were significantly higher in both the DN and BH groups than in the NC group (P < 0.05). Compared with the DN group, proteinuria, urea, creatinine, triglycerides and total cholesterol levels were decreased, whereas the albumin level was increased after BH treatment (all P < 0.05). Furthermore, BH diminished kidney volume and ameliorated the pathological changes associated with DN. ANGPTL-4 expression was significantly decreased after BH treatment, and ANGPTL-4 expression was highly correlated with biochemical indicators of DN (P < 0.05). These results suggest that benazepril hydrochloride improves DN and decreases proteinuria by decreasing ANGPTL-4 expression. Reference: BMC Nephrol. 2017 Oct 4;18(1):307. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628429/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMF	30.0	65.08
	DMF:PBS (pH 7.2) (1:1)	0.5	1.08
	DMSO	64.5	139.99
	Ethanol	46.5	100.88
	Water	26.0	56.47

Preparing Stock Solutions

The following data is based on the product molecular weight 460.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Li H, Wang Y, Zhou Z, Tian F, Yang H, Yan J. Combination of leflunomide and benazepril reduces renal injury of diabetic nephropathy rats and inhibits high-glucose induced cell apoptosis through regulation of NF-κB, TGF-β and TRPC6. Ren Fail. 2019 Nov;41(1):899-906. doi: 10.1080/0886022X.2019.1665547. PMID: 31552773; PMCID: PMC6764370. 2. Xue L, Feng X, Wang C, Zhang X, Sun W, Yu K. Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria by decreasing ANGPTL-4 expression. BMC Nephrol. 2017 Oct 4;18(1):307. doi: 10.1186/s12882-017-0724-1. PMID: 28978304; PMCID: PMC5628429.
In vitro protocol:	1. Li H, Wang Y, Zhou Z, Tian F, Yang H, Yan J. Combination of leflunomide and benazepril reduces renal injury of diabetic nephropathy rats and inhibits high-glucose induced cell apoptosis through regulation of NF-κB, TGF-β and TRPC6. Ren Fail. 2019 Nov;41(1):899-906. doi: 10.1080/0886022X.2019.1665547. PMID: 31552773; PMCID: PMC6764370.
In vivo protocol:	1. Xue L, Feng X, Wang C, Zhang X, Sun W, Yu K. Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria by decreasing ANGPTL-4 expression. BMC Nephrol. 2017 Oct 4;18(1):307. doi: 10.1186/s12882-017-0724-1. PMID: 28978304; PMCID: PMC5628429.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Zhang Q, Ji Y, Lv W, He T, Wang J. Protective effects of leflunomide on renal
lesions in a rat model if diabetic nephropathy. Ren Fail. 2015 Oct 29:1-7. [Epub
ahead of print] PubMed PMID: 26512931.

2: Benazepril in dogs with asymptomatic mitral valve disease. Vet Rec. 2015 Oct
17;177(15):392. doi: 10.1136/vr.h4110. PubMed PMID: 26475899.

3: Sent U, Gössl R, Elliott J, Syme HM, Zimmering T. Comparison of Efficacy of
Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic
Kidney Disease. J Vet Intern Med. 2015 Nov;29(6):1479-87. doi:
10.1111/jvim.13639. Epub 2015 Oct 16. PubMed PMID: 26474314.

4: Gismondi RA, Bedirian R, Pozzobon CR, Ladeira MC, Oigman W, Neves MF.
Renin-Angiotensin System Blockade Associated with Statin Improves Endothelial
Function in Diabetics. Arq Bras Cardiol. 2015 Oct 2. pii:
S0066-782X2015005050123. [Epub ahead of print] Portuguese, English. PubMed PMID:
26465872.

5: Marcondes-Santos M, Mansur AP, Fragata FS, Strunz CM. Short-term follow-up of
exercise training program and beta-blocker treatment on quality of life in dogs
with naturally acquired chronic mitral valve disease. Braz J Med Biol Res. 2015
Oct;48(10):886-94. doi: 10.1590/1414-431X20154568. Epub 2015 Aug 4. PubMed PMID:
26445331.

6: Mochel JP, Danhof M. Chronobiology and Pharmacologic Modulation of the
Renin-Angiotensin-Aldosterone System in Dogs: What Have We Learned? Rev Physiol
Biochem Pharmacol. 2015 Oct 2. [Epub ahead of print] PubMed PMID: 26428686.

7: Jenkins TL, Coleman AE, Schmiedt CW, Brown SA. Attenuation of the pressor
response to exogenous angiotensin by angiotensin receptor blockers and benazepril
hydrochloride in clinically normal cats. Am J Vet Res. 2015 Sep;76(9):807-13.
doi: 10.2460/ajvr.76.9.807. PubMed PMID: 26309109.

8: Marcondes-Santos M, Mansur AP, Fragata FS, Strunz CM. Short-term follow-up of
exercise training program and beta-blocker treatment on quality of life in dogs
with naturally acquired chronic mitral valve disease. Braz J Med Biol Res. 2015
Aug 4:0. [Epub ahead of print] PubMed PMID: 26270326.

9: Qian M, Chen T, Zhou D, Zhang Z, Zhang Q, Tang S, Xiao X. Development of a new
benazepril hydrochloride chewable tablet and evaluation of its bioequivalence for
treatment of heart failure in dogs. J Vet Pharmacol Ther. 2015 Jul 30. doi:
10.1111/jvp.12252. [Epub ahead of print] PubMed PMID: 26228576.

10: Zhang YU, Zhou N, Wang H, Wang S, He J. Effect of Shenkang granules on the
progression of chronic renal failure in 5/6 nephrectomized rats. Exp Ther Med.
2015 Jun;9(6):2034-2042. Epub 2015 Mar 24. PubMed PMID: 26136932; PubMed Central
PMCID: PMC4473336.

11: Xiao X, Wang J, Chang X, Zhen J, Zhou G, Hu Z. Mycophenolate mofetil
ameliorates diabetic nephropathy through epithelial mesenchymal transition in
rats. Mol Med Rep. 2015 Sep;12(3):4043-50. doi: 10.3892/mmr.2015.3934. Epub 2015
Jun 15. PubMed PMID: 26080907.

12: Zhang Y, Zhou N, Li T, Wang HY, He JY. [Effect of Shenkang Injection on
Kidney Function in Hypertensive Renal Damage Rats]. Zhong Yao Cai. 2014
Dec;37(12):2248-54. Chinese. PubMed PMID: 26080514.

13: Shen S, Yang X, Shi Y. Application of quantitative NMR for purity
determination of standard ACE inhibitors. J Pharm Biomed Anal. 2015 Oct
10;114:190-9. doi: 10.1016/j.jpba.2015.05.021. Epub 2015 May 27. PubMed PMID:
26070161.

14: Zhu C, Luo Y. [Clinical controlled trial on chronic nephritis albuminuria
treated with acupuncture and moxibustion at DONG's extra points, "Xiasanhuana"].
Zhongguo Zhen Jiu. 2015 Apr;35(4):335-8. Chinese. PubMed PMID: 26054140.

15: Jallapally A, Addla D, Bagul P, Sridhar B, Banerjee SK, Kantevari S. Design,
synthesis and evaluation of novel 2-butyl-4-chloroimidazole derived
peptidomimetics as Angiotensin Converting Enzyme (ACE) inhibitors. Bioorg Med
Chem. 2015 Jul 1;23(13):3526-33. doi: 10.1016/j.bmc.2015.04.024. Epub 2015 Apr
16. PubMed PMID: 25922179.

16: Zou X, Zhang XX, Liu XY, Li R, Wang M, Wu WJ, Sui Y, Zhao HL. Renal
kallikrein activation and renoprotection after dual blockade of renin-angiotensin
system in diet-induced diabetic nephropathy. J Diabetes Res. 2015;2015:310645.
doi: 10.1155/2015/310645. Epub 2015 Mar 30. PubMed PMID: 25918729; PubMed Central
PMCID: PMC4397032.

17: Lee IT, Sheu WH, Hung YJ, Chen JF, Wang CY, Lee WJ. Assessment of glomerular
filtration rate based on alterations of serum brain-derived neurotrophic factor
in type 2 diabetic subjects treated with amlodipine/benazepril or
valsartan/hydrochlorothiazide. Dis Markers. 2015;2015:780743. doi:
10.1155/2015/780743. Epub 2015 Mar 30. PubMed PMID: 25918454; PubMed Central
PMCID: PMC4397057.

18: Peng DF, Tang SY, Hu YJ, Chen J, Peng X, Huang Q. Comparison of valsartan and
benazepril when combined with atorvastatin in protecting patients with early
cardio-renal syndrome (CRS). Eur Rev Med Pharmacol Sci. 2015 Apr;19(7):1264-71.
PubMed PMID: 25912588.

19: Daina E, Cravedi P, Alpa M, Roccatello D, Gamba S, Perna A, Gaspari F,
Remuzzi G, Ruggenenti P. A multidrug, antiproteinuric approach to alport
syndrome: a ten-year cohort study. Nephron. 2015;130(1):13-20. doi:
10.1159/000381480. Epub 2015 Apr 21. PubMed PMID: 25895746; PubMed Central PMCID:
PMC4451141.

20: Tang X, Hu X, Mei C, Yu S. Improvement of resistant hypertension by nocturnal
hemodialysis in a patient with end-stage kidney disease. Case Rep Nephrol Dial.
2015 Feb 17;5(1):60-5. doi: 10.1159/000377671. eCollection 2015 Jan-Apr. PubMed
PMID: 25874195; PubMed Central PMCID: PMC4376926.

Your view history

Benazepril hydrochloride featured